These data suggest that d-allulose may moderately enhance energy expenditure, which might additionally contribute to attenuation of visceral obesity, in agreement with previous reports that d-allulose increases energy expenditure 29
For tirzepatide in the SURMOUNT-1 trial, nausea rates ranged from 25-33% depending on the dose, with higher doses associated with increased incidence
We assume no experience and coach from the first rep
GLP-1 levels can fluctuate based on food intake and timing
As of 02/05/2026, no clinical trials have been completed testing the efficacy of GLP-1RAs (GLP-1 RAs) in treating opioid use disorder (OUD), cocaine use disorder, or other stimulant use disorders
While the Bonati Spine Institute is located in the Tampa Bay area, patients from all over the world have sought Dr